WHO Members Extend Pandemic-Treaty Talks as PABS Annex Stalls

The World Health Organization's member states ended the resumed sixth meeting of the Intergovernmental Working Group on the WHO Pandemic Agreement in Geneva on 1 May 2026 without finalising the most contested annex of the treaty: the Pathogen Access and Benefit Sharing system, known as PABS. Negotiations will resume from 6 to 17 July at a seventh meeting, with the outcome ultimately destined for the 2027 World Health Assembly or — if member states agree — an earlier special session in 2026.

What PABS is

PABS is intended to be the operational core of the Pandemic Agreement: a system through which countries quickly share pathogens with pandemic potential and, in return, receive fair access to the vaccines, diagnostics and therapeutics those pathogens enable. The fundamental quid-pro-quo dates back to the 2014 Ebola response and the 2007 Indonesia H5N1 dispute, both of which exposed the moral hazard of a system in which low-income countries provide the biological samples and high-income countries get the vaccines.

Where the disagreement lies

Three substantive blocks. First, the share of vaccine and therapeutic production allocated to WHO for distribution to PABS contributors — proposals range widely. Second, the legal nature of pharmaceutical industry obligations: voluntary, contractual, or treaty-binding. Third, intellectual property: the extent to which PABS triggers compulsory licensing, technology transfer or other concessions. None of these is fully resolved.

What the leadership said

WHO Director-General Tedros Adhanom Ghebreyesus said member states should "continue approaching outstanding issues with urgency because the next pandemic is a matter of when, not if." IGWG co-chair Ambassador Tovar da Silva Nunes of Brazil said: "With an extension of our negotiations, we will get there." Co-chair Matthew Harpur described the work as "moving in the right direction to finalise the PABS annex." Diplomatic statements; the substance is harder.

The US shadow

The United States announced its withdrawal from the WHO under the second Trump administration in January 2026. The withdrawal does not formally remove the US from PABS negotiations — non-WHO members can engage as observers — but it has taken the largest single biopharmaceutical economy out of the treaty's binding ambit. The implications run in both directions: less pressure to ratify, less leverage on US-headquartered manufacturers, and more space for emerging-market positions to set the terms.

What it means in practice

Even without PABS, the broader Pandemic Agreement architecture continues. The agreement covers prevention, preparedness, supply chains, governance and financing. PABS is the most operationally consequential annex but not the only one. The risk of failure on PABS is less that the entire agreement collapses and more that it becomes a treaty that promises preparedness without an enforceable mechanism for sharing pathogens or distributing the resulting countermeasures fairly. That would be, in functional terms, a loud no.